Rong Jin1, Adam Y Xiao1, Rui Chen1, D Neil Granger1, Guohong Li2. 1. From the Department of Neurosurgery, Pennsylvania State University College of Medicine, Hershey (R.J., G.L.); and Department of Neurosurgery (R.C., R.J., G.L.) and the Department of Molecular and Cellular Physiology (A.Y.X., G.L., D.N.G.), Louisiana State University Health Sciences Center, Shreveport. 2. From the Department of Neurosurgery, Pennsylvania State University College of Medicine, Hershey (R.J., G.L.); and Department of Neurosurgery (R.C., R.J., G.L.) and the Department of Molecular and Cellular Physiology (A.Y.X., G.L., D.N.G.), Louisiana State University Health Sciences Center, Shreveport. guohongli@pennstatehealth.psu.edu.
Abstract
BACKGROUND AND PURPOSE: Inflammation and thrombosis currently are recognized as critical contributors to the pathogenesis of ischemic stroke. CD147 (cluster of differentiation 147), also known as extracellular matrix metalloproteinase inducer, can function as a key mediator of inflammatory and immune responses. CD147 expression is increased in the brain after cerebral ischemia, but its role in the pathogenesis of ischemic stroke remains unknown. In this study, we show that CD147 acts as a key player in ischemic stroke by driving thrombotic and inflammatory responses. METHODS: Focal cerebral ischemia was induced in C57BL/6 mice by a 60-minute transient middle cerebral artery occlusion. Animals were treated with anti-CD147 function-blocking antibody (αCD147) or isotype control antibody. Blood-brain barrier permeability, thrombus formation, and microvascular patency were assessed 24 hours after ischemia. Infarct size, neurological deficits, and inflammatory cells invaded in the brain were assessed 72 hours after ischemia. RESULTS: CD147 expression was rapidly increased in ischemic brain endothelium after transient middle cerebral artery occlusion. Inhibition of CD147 reduced infarct size and improved functional outcome on day 3 after transient middle cerebral artery occlusion. The neuroprotective effects were associated with (1) prevented blood-brain barrier damage, (2) decreased intravascular fibrin and platelet deposition, which in turn reduced thrombosis and increased cerebral perfusion, and (3) reduced brain inflammatory cell infiltration. The underlying mechanism may include reduced NF-κB (nuclear factor κB) activation, MMP-9 (matrix metalloproteinase-9) activity, and PAI-1 (plasminogen activator inhibitor-1) expression in brain microvascular endothelial cells. CONCLUSIONS: Inhibition of CD147 ameliorates acute ischemic stroke by reducing thromboinflammation. CD147 might represent a novel and promising therapeutic target for ischemic stroke and possibly other thromboinflammatory disorders.
BACKGROUND AND PURPOSE:Inflammation and thrombosis currently are recognized as critical contributors to the pathogenesis of ischemic stroke. CD147 (cluster of differentiation 147), also known as extracellular matrix metalloproteinase inducer, can function as a key mediator of inflammatory and immune responses. CD147 expression is increased in the brain after cerebral ischemia, but its role in the pathogenesis of ischemic stroke remains unknown. In this study, we show that CD147 acts as a key player in ischemic stroke by driving thrombotic and inflammatory responses. METHODS:Focal cerebral ischemia was induced in C57BL/6 mice by a 60-minute transient middle cerebral artery occlusion. Animals were treated with anti-CD147 function-blocking antibody (αCD147) or isotype control antibody. Blood-brain barrier permeability, thrombus formation, and microvascular patency were assessed 24 hours after ischemia. Infarct size, neurological deficits, and inflammatory cells invaded in the brain were assessed 72 hours after ischemia. RESULTS:CD147 expression was rapidly increased in ischemic brain endothelium after transient middle cerebral artery occlusion. Inhibition of CD147 reduced infarct size and improved functional outcome on day 3 after transient middle cerebral artery occlusion. The neuroprotective effects were associated with (1) prevented blood-brain barrier damage, (2) decreased intravascular fibrin and platelet deposition, which in turn reduced thrombosis and increased cerebral perfusion, and (3) reduced brain inflammatory cell infiltration. The underlying mechanism may include reduced NF-κB (nuclear factor κB) activation, MMP-9 (matrix metalloproteinase-9) activity, and PAI-1 (plasminogen activator inhibitor-1) expression in brain microvascular endothelial cells. CONCLUSIONS: Inhibition of CD147 ameliorates acute ischemic stroke by reducing thromboinflammation. CD147 might represent a novel and promising therapeutic target for ischemic stroke and possibly other thromboinflammatory disorders.
Authors: Deidre A De Silva; John N Fink; Soren Christensen; Martin Ebinger; Christopher Bladin; Christopher R Levi; Mark Parsons; Ken Butcher; P Alan Barber; Geoffrey A Donnan; Stephen M Davis Journal: Stroke Date: 2009-05-28 Impact factor: 7.914
Authors: Arthur Liesz; Wei Zhou; Éva Mracskó; Simone Karcher; Henrike Bauer; Sönke Schwarting; Li Sun; Dunja Bruder; Sabine Stegemann; Adelheid Cerwenka; Clemens Sommer; Alexander H Dalpke; Roland Veltkamp Journal: Brain Date: 2011-03 Impact factor: 13.501
Authors: Eva Göb; Stephan Reymann; Friederike Langhauser; Michael K Schuhmann; Peter Kraft; Ina Thielmann; Kerstin Göbel; Marc Brede; György Homola; László Solymosi; Guido Stoll; Christian Geis; Sven G Meuth; Bernhard Nieswandt; Christoph Kleinschnitz Journal: Ann Neurol Date: 2015-03-13 Impact factor: 10.422
Authors: Shashank Shekhar; Mark W Cunningham; Mallikarjuna R Pabbidi; Shaoxun Wang; George W Booz; Fan Fan Journal: Eur J Pharmacol Date: 2018-06-20 Impact factor: 4.432
Authors: Raul R Rodrigues-Diez; Antonio Tejera-Muñoz; Laura Marquez-Exposito; Sandra Rayego-Mateos; Laura Santos Sanchez; Vanessa Marchant; Lucía Tejedor Santamaria; Adrian M Ramos; Alberto Ortiz; Jesus Egido; Marta Ruiz-Ortega Journal: Br J Pharmacol Date: 2020-07-15 Impact factor: 8.739